{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:11:44Z","timestamp":1791670304485,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.critrevonc.2025.104676","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:01:53Z","timestamp":1741478513000},"page":"104676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Consolidative radiotherapy in oligometastatic and oligoprogressive NSCLC: A systematic review"],"prefix":"10.1016","volume":"210","author":[{"given":"Nazmul","family":"Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5308-615X","authenticated-orcid":false,"given":"Misako","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.critrevonc.2025.104676_bib1","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104676_bib2","first-page":"115","article-title":"Stereotactic ablative radiotherapy for oligo-progressive disease refractory to systemic therapy in non-small cell lung cancer: a registry-based phase II randomized trial (SUPPRESS-NSCLC)","volume":"34","author":"Bahig","year":"2022","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104676_bib3","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/bjc.1997.123","article-title":"A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer","volume":"75","author":"Ball","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104676_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000537","article-title":"Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma","volume":"8","author":"Barsoumian","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104676_bib5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after locally ablative therapy for oligometastatic non-small cell lung cancer: a single-arm, phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104676_bib6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0360-3016(02)02989-9","article-title":"Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15)","volume":"54","author":"Bezjak","year":"2002","journal-title":"Int. J. Radiat. Oncol., Biol., Phys."},{"key":"10.1016\/j.critrevonc.2025.104676_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2020.12.029","article-title":"Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: a prospective phase 2 study","volume":"152","author":"Blake-Cerda","year":"2021","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104676_bib8","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104676_bib9","first-page":"117","article-title":"Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond","volume":"55","author":"Bucci","year":"2005","journal-title":"CA: A Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104676_bib10","first-page":"929","article-title":"Avoiding toxicity with lung radiation therapy: an IASLC perspective","volume":"17","author":"Bucknell","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104676_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1470-2045(20)30537-4","article-title":"Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study","volume":"22","author":"Chalkidou","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104676_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2020.02.002","article-title":"ATOM: a phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI","volume":"142","author":"Chan","year":"2020","journal-title":"Lung Cancer"},{"issue":"10405","key":"10.1016\/j.critrevonc.2025.104676_bib13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104676_bib14","article-title":"Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer","volume":"8","author":"Conibear","year":"2018","journal-title":"BMJ Open"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104676_bib15","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs concurrent chemoradiation for stage III non\u2013small cell lung cancer: Randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104676_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2008.02.015","article-title":"Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC)","volume":"62","author":"Decoster","year":"2008","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104676_bib17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.21037\/tlcr.2017.04.04","article-title":"Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy","volume":"6","author":"Diwanji","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104676_bib18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3390\/cancers16061206","article-title":"Adaptive radiotherapy: next-generation radiotherapy","volume":"16","author":"Dona Lemus","year":"2024","journal-title":"Cancers"},{"issue":"ement 8","key":"10.1016\/j.critrevonc.2025.104676_bib19","doi-asserted-by":"crossref","first-page":"viii547","DOI":"10.1093\/annonc\/mdy292.130","article-title":"Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)","volume":"29","author":"Elamin","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104676_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.radonc.2019.10.013","article-title":"Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors","volume":"144","author":"Finazzi","year":"2020","journal-title":"Radiother. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104676_bib21","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104676_bib22","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104676_bib23","article-title":"Mechanisms of action of radiotherapy combined with systemic therapies","author":"Hasan","year":"2024","journal-title":"Creat. BioRender. Com."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104676_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.adro.2018.10.003","article-title":"Stereotactic MR-guided online adaptive radiation therapy (SMART) for ultracentral thorax malignancies: results of a phase 1 trial","volume":"4","author":"Henke","year":"2019","journal-title":"Adv. Radiat. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104676_bib25","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","article-title":"NRG-LU002: randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)","volume":"42","author":"Iyengar","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104676_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104676_bib27","doi-asserted-by":"crossref","first-page":"11061","DOI":"10.3390\/ijms222011061","article-title":"The abscopal effect: a review of pre-clinical and clinical advances","volume":"22","author":"Janopaul-Naylor","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104676_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003778","article-title":"Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab","volume":"10","author":"Jazieh","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104676_bib29","first-page":"491","article-title":"A multicenter two-arm, phase II trial assessing the safety and efficacy of first-line lazertinib and locally ablative radiotherapy in patients with synchronous oligo-metastatic EGFR-mutant non-small cell lung cancer (ABLATE, KCSG-LU21-11)","volume":"23","author":"Kim","year":"2022","journal-title":"Clin. Lung Cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104676_bib30","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2017.74.0720","article-title":"Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer","volume":"36","author":"Liao","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104676_bib31","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/jamaoncol.2021.7664","article-title":"Palliative radiation for advanced central lung tumors with intentional avoidance of the esophagus (PROACTIVE): A phase 3 randomized clinical trial","volume":"8","author":"Louie","year":"2022","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104676_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/bjc.1991.62","article-title":"Inoperable non-small-cell lung cancer (NSCLC): a medical research council randomized trial of palliative radiotherapy with two fractions or ten fractions","volume":"63","author":"Medical Research Council Lung Cancer Working Party","year":"1991","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104676_bib33","article-title":"A review of proton therapy \u2013 current status and future directions","volume":"6","author":"Mohan","year":"2022","journal-title":"Proton Ther."},{"issue":"10185","key":"10.1016\/j.critrevonc.2025.104676_bib34","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104676_bib35","article-title":"Initial clinical experience building a dual CT- and MR-guided adaptive radiotherapy program","volume":"42","author":"Price","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104676_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.prro.2011.01.005","article-title":"Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline","volume":"1","author":"Rodrigues","year":"2011","journal-title":"Pract. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104676_bib37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1378\/chest.117.2.358","article-title":"Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: radiation therapy oncology group, eastern cooperative oncology group, and southwest oncology group","volume":"117","author":"Sause","year":"2000","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104676_bib38","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.ijrobp.2023.06.353","article-title":"Stereotactic ablative radiotherapy for oligo-progressive cancers: Results of the randomized phase II STOP trial","volume":"117","author":"Schellenberg","year":"2023","journal-title":"Int. J. Radiat. Oncol., Biol., Phys."},{"key":"10.1016\/j.critrevonc.2025.104676_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41698-023-00440-6","article-title":"Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer","volume":"7","author":"Semenkovich","year":"2023","journal-title":"NPJ Precis. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104676_bib40","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104676_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109741","article-title":"Ultra-high dose-rate proton FLASH improves tumor control","volume":"186","author":"Shukla","year":"2023","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104676_bib42","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: A Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104676_bib43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.23.02075","article-title":"Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: a multicenter, randomized, controlled, phase III trial","volume":"43","author":"Sun","year":"2025","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104676_bib44","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non\u2013small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol."},{"issue":"10422","key":"10.1016\/j.critrevonc.2025.104676_bib45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104676_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100160","article-title":"Circulating tumor DNA kinetics: a future tool for radiation therapy personalization in lung cancer?","volume":"6","author":"Walls","year":"2024","journal-title":"J. Liq. Biopsy"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104676_bib47","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104676_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104676_bib49","article-title":"Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents","volume":"10","author":"Wrona","year":"2021","journal-title":"J. Thorac. Dis."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104676_bib50","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.3390\/cancers12102762","article-title":"Radiotherapy-mediated immunomodulation and anti-tumor abscopal effect combining immune checkpoint blockade","volume":"12","author":"Zhao","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104676_bib51","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.21037\/tlcr-22-644","article-title":"International consensus on radiotherapy in metastatic non-small cell lung cancer","volume":"11","author":"Zhu","year":"2022","journal-title":"Transl. Lung Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:04:35Z","timestamp":1746767075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825000642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":51,"alternative-id":["S1040842825000642"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104676","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consolidative radiotherapy in oligometastatic and oligoprogressive NSCLC: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104676"}}